Table.
Demographic and treatment data for the entire cohort.
|
Patient no. |
Age, y |
Sex |
Prior chemotherapy |
Surgery |
Time to PBT, mo |
Initial volume, cm3 |
Response |
Intervention (time since PBT, mo) |
Notes |
| 1 | 10 | M | Carboplatin, vincristine, pyrrolidine dithiocarbamate | Yes | 6.7 | 40.7 | Pseudoprogression | ΔShunt (90.1) | 5940 cGyE |
| 2 | 8 | F | Carboplatin, vincristine, actinomycin D, temozolomide, O6-benzylguanine, lomustine, thioguanine, procarbazine | Yes | 46.0 | 50.72 | Nonresponder | ΔShunt (7.8) | Deceased, 9.6 mo after PBT |
| 3 | 6 | M | Carboplatin, vincristine, cisplatin, etoposide | Yes ×2 | 27.5 | 57.96 | Pseudoprogression | Chemotherapy for T-cell ALL (21.9) | Second malignancy |
| 4 | 6 | M | Carboplatin, vincristine, temozolomide, vinblastine | Yes ×2 | 6.6 | 7.55 | Nonresponder | Hyperbaric O2 (87.8) | |
| 5 | 5 | M | Carboplatin, vincristine | Yes ×2 | 7.3 | 9.26 | Pure responder | None | |
| 6 | 12 | F | Carboplatin, vincristine, lomustine, procarbazine, temozolomide | No | N/A | 14.75 | Nonresponder | Hyperbaric O2 (25.4) | Prior radiotherapy; biopsy-proven radionecrosis |
| 7 | 4 | M | Cisplatin, vincristine, temozolomide | Yes | 46.0 | 13.23 | Pure responder | ΔShunt (38.6) | |
| 8 | 8 | F | Carboplatin, vincristine, gefitinib | No | N/A | 46.56 | Pure responder | Cyst drainage (23.4) | 5040 cGyE |
| 9 | 17 | M | None | Yes | 3.1 | 15.15 | Pure responder | None | |
| 10 | 16 | F | None | No | N/A | 3.37 | Pure responder | None | |
| 11 | 14 | M | None | Yes | 3.1 | 1.60 | Pure responder | None | |
| 12 | 10 | F | None | No | N/A | 14.13 | Nonresponder | Chemotherapy (7.7) | |
| 13 | 20 | M | None | Yes | 17.3 | 3.15 | Pseudoprogression | None | |
| 14 | 11 | M | Carboplatin, vincristine | Yes | 93.9 | 20.93 | Pure responder | None | |
| 15 | 16 | F | None | No | N/A | 8.86 | Pure responder | None |
Abbreviations: PBT, proton beam therapy; F, female; M, male; ALL, acute lymphoblastic leukemia; O2, oxygen; N/A, not applicable; cGyE, centigray equivalents; .